Researchers at Dana-Farber Cancer Institute and affiliated organizations report that in a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine.
The findings will be published by the Journal of Clinical Oncology on its Web site and later in a print edition.
No User Responded In This Post
Before Leave Your Comments Here Click Below On Our Sponsors...